Mustang Bio (NASDAQ: MBIO)
Mustang Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Mustang Bio Company Info
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
News & Analysis
Why Mustang Bio Stock Galloped Higher Today
The biotech announced a clinical update and an analyst initiated coverage on the stock.
Why Mustang Bio Stock Is On Fire Today
A new gene therapy could be a functional cure for "bubble boy" disease.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.